New Analyses of Kite's Tecartus® CAR T-Cell Therapy Provide Additional Evidence Supporting Overall Survival and Durability of Response Pharmaceutical Investing
Clene Announces Closing of $5 Million Debt Facility from the State of Maryland Life Science Investing
Cardiol Therapeutics Commences Multi-Center Phase II Pilot Study of CardiolRx for the Treatment of Recurrent Pericarditis Pharmaceutical Investing
Bristol Myers Squibb Announces First Disclosures and New Data at ASH 2022, Demonstrating Commitment to Raising Standards in Treatment Through Broad Multiple Myeloma Portfolio Pharmaceutical Investing
AMGEN TO HOST WEBCAST INVESTOR CALL FOLLOWING ANNOUNCED ACQUISITION OF HORIZON THERAPEUTICS Market News
AbbVie Presents Data at the 64th American Society of Hematology Annual Meeting Evaluating Epcoritamab Across B-Cell Lymphomas Pharmaceutical Investing
Body of Evidence Grows From ZUMA-7 Study Supporting Initial Treatment With Kite's Yescarta® CAR T-cell Therapy for Patients With Relapsed or Refractory Large B-cell Lymphoma Pharmaceutical Investing
Time to CAR T-cell Therapy May Impact Outcomes for Patients With Relapsed/Refractory Large B-cell Lymphoma in New CIBMTR Analysis Pharmaceutical Investing
Aptose Announces Updated Clinical Responses, Breadth of Activity, and Safety Across Four Dose Levels of Tuspetinib in Difficult-to-Treat Acute Myeloid Leukemia Populations Market News
AbbVie Presents Data at the 64th American Society of Hematology Annual Meeting for Investigational Navitoclax in Combination With Ruxolitinib for JAK Inhibitor-Naïve Myelofibrosis Patients Pharmaceutical Investing
